報價延遲最少15分鐘:2025/07/10 23:12 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.18 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.56/2.35
|
|
企業價值
918.60M
|
| 資產負債 |
|
每股賬面淨值
1.17
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/10 23:12 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066. |